Other languages Nektar Therapeutics

Equities

NKTR

US6402681083

Real-time Estimate Cboe BZX Other stock markets 03:47:16 2024-04-23 pm EDT			5-day change	1st Jan Change
1.415 ^USD	+4.04%		-5.03%	+150.44%

Mar. 19	Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	CI
Mar. 05	Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	Mar. 05
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	Mar. 05
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	Jan. 22
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255	Dec. 12
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Nektar Therapeutics Says Rezpegaldesleukin Trial Data Showed 'Consistent Benefit' to Treat Atopic Dermatitis	23-10-13
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy	23-10-13
Nektar Therapeutics, Cellular Biomedicine Collaborate to Evaluate Lung Cancer Drugs	23-09-27
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer	23-09-27
Nektar Therapeutics' Trial of Chronic Skin Condition Treatment Yields 'Statistically Significant Results'	23-09-13
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis	23-09-13
Nektar Therapeutics Provides Earnings Guidance for the Year 2023	23-08-08
Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	23-08-07
Sector Update: Health Care	23-08-07
Nektar Therapeutics Sues Eli Lilly in California Over Autoimmune Disease Therapy Claims	23-08-07
Top Midday Gainers	23-08-07
Nektar Therapeutics Says Corrected Data From Studies of Eczema Drug Showed 83% Improvement Rate; Shares Jump	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nektar Therapeutics

Equities

NKTR

US6402681083

Other languages

Filters